Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe) by Thurtle, David et al.
RESEARCH ARTICLE Open Access
Comparative performance and external
validation of the multivariable PREDICT
Prostate tool for non-metastatic prostate
cancer: a study in 69,206 men from
Prostate Cancer data Base Sweden
(PCBaSe)
David Thurtle1*, Ola Bratt2, Pär Stattin3, Paul Pharoah4† and Vincent Gnanapragasam5†
Abstract
Background: PREDICT Prostate is an endorsed prognostic model that provides individualised long-term prostate
cancer-specific and overall survival estimates. The model, derived from UK data, estimates potential treatment
benefit on overall survival. In this study, we externally validated the model in a large independent dataset and
compared performance to existing models and within treatment groups.
Methods: Men with non-metastatic prostate cancer and prostate-specific antigen (PSA) < 100 ng/ml diagnosed
between 2000 and 2010 in the nationwide population-based Prostate Cancer data Base Sweden (PCBaSe) were
included. Data on age, PSA, clinical stage, grade group, biopsy involvement, primary treatment and comorbidity
were retrieved. Sixty-nine thousand two hundred six men were included with 13.9 years of median follow-up.
Fifteen-year survival estimates were calculated using PREDICT Prostate for prostate cancer-specific mortality (PCSM)
and all-cause mortality (ACM). Discrimination was assessed using Harrell’s concordance (c)-index in R. Calibration
was evaluated using cumulative available follow-up in Stata (TX, USA).
Results: Overall discrimination of PREDICT Prostate was good with c-indices of 0.85 (95% CI 0.85–0.86) for PCSM
and 0.79 (95% CI 0.79–0.80) for ACM. Overall calibration of the model was excellent with 25,925 deaths predicted
and 25,849 deaths observed. Within the conservative management and radical treatment groups, c-indices for 15-
year PCSM were 0.81 and 0.78, respectively. Calibration also remained good within treatment groups. The discrimination of
PREDICT Prostate significantly outperformed the EAU, NCCN and CAPRA scores for both PCSM and ACM within this cohort
overall.
A key limitation is the use of retrospective cohort data.
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Conclusions: This large external validation demonstrates that PREDICT Prostate is a robust and generalisable model to aid
clinical decision-making.
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Background
Prostate cancer represents a growing burden on health
care globally, with increasing numbers and proportions of
men presenting with non-metastatic prostate cancer (PCa)
[1]. Alongside this, there has been increased confidence in
the use of conservative management (active surveillance
and watchful waiting) [2]. Understanding disease progno-
sis to guide treatment decision-making is therefore of
great importance. However, until recently, no high-quality
individualised model for survival existed.
Using data from over 10,000 UK men, we have previ-
ously published an individualised prognostic model for
cancer-specific and overall survival called ‘PREDICT
Prostate’ [3]. PREDICT Prostate (available online [4])
provides cancer-specific and overall percentage survival
estimates for up to 15 years and has been endorsed by
the National Institute for Health and Care Excellence
(NICE) [5]. To maximise usability, it uses routinely avail-
able clinico-pathological data (age, PSA, grade, stage, bi-
opsy involvement, treatment type and comorbidity). It
represents real-world data from a non-screened, primary
diagnostic cohort, including a significant number of men
treated conservatively. Crucially, the model also allows
adjustment for competing mortalities by incorporating
both cancer-specific and non-cancer survival outcomes
to contextualise the diagnosis as part of a decision aid.
Internal validation and accuracy within a small external
population were promising during model development
[3]. However, external validation in independent cohorts,
ideally in a different location, is vital to demonstrate
generalisability and accuracy of a multivariable prognos-
tic model [6].
The Prostate Cancer data Base Sweden (PCBaSe) is
one of the largest and most comprehensive prostate can-
cer cohorts world-wide and is well suited for external
validation of PREDICT Prostate [7]. The aim of this
study was to validate PREDICT Prostate and compare
performance to existing models.
Methods
Source of data
Data from PCBaSE 3.0 were used, according to a pre-
specified project outline (Additional file 2) [8–10].
PCBaSe was created by the combination of the National
Prostate Cancer Register of Sweden with other national
healthcare and demographic databases [11]. The capture
rate of this register is 98% of all incident prostate cancer
cases compared to the Swedish Cancer Registry—to which
registration is mandated by law [12]. The cause of death
information is updated from the Cause of Death Registry
which captures all deaths in Sweden. The agreement be-
tween the recorded cause of death and reviewed medical
records has been reported at 86% (95% CI 85–87%) [13].
Participants and predictors
We included men within PCBaSe diagnosed with PCa
between 1 January 2000 and 31 December 2010, with no
evidence of metastatic disease and prostate-specific anti-
gen (PSA) < 100 ng/ml. Cases were censored at death,
migration or 31 December 2016, whichever event
occurred first. Data were available for 82,936 men. Out-
come events were ‘PCa death’ or ‘any-cause death’ from
which ‘non-PCa death’ was derived. Intact data were re-
quired for variables mandatory within the model: age,
PSA, T stage, histological grade group, primary treat-
ment type and comorbidity. This led to the exclusion of
13,730 (16.6%) cases, leaving a final analysable dataset of
69,206 (Table 1). Missing data were most abundant for
the histological grade group (n = 8117), as primary and
secondary Gleason grades were not always registered.
Data were also missing on PSA (n = 2124), T stage (n =
1364), age (n = 4) and primary treatment (n = 3960).
Some men had missing data for more than one variable.
All variables were determined at the time of diagnosis.
Biopsy characteristics are an optional variable in the
PREDICT Prostate model; therefore, missing data on
proportion of positive cores ([PPC] = number of cores
with any cancer/number of cores taken) were tolerated.
We also re-tested the value of PPC to predict PCa death
in a sub-group with intact biopsy information (n = 44,
163) using the same method as previously [3]. Primary
treatment was defined as the radical treatment received
up to 12months after the date of diagnosis, or conserva-
tive management. The same definition of comorbidity
was used as in the model development: the combination
of both Charlson Comorbidity Index of 1 or greater (ex-
cluding PCa) and a hospital admission in the 2 years pre-
ceding PCa diagnosis [3]. Up to 2008, the treatment
strategies of active surveillance and watchful waiting
were reported as conservative management. After 2008,
these strategies were registered as separate entities. We
used conservative management as a treatment strategy
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also for men diagnosed after 2008, although a small,
well-defined active surveillance group was separately
analysed.
Outcome
The model estimates prostate cancer-specific mortality
(PCSM), non-PCa mortality (NPCM) and overall or all-
cause mortality (ACM), counted from the time of
diagnosis. It provides estimates following conservative
management and radical treatment (by either radical
prostatectomy or radiotherapy).
Statistical analysis methods
Beta coefficients for each prognostic factor in the model
were applied to derive prognostic indices for PCSM and
NPCM for each patient. These were used in
Table 1 Baseline cohort characteristics in the original UK model development cohort and Prostate Cancer data Base Sweden
(PCBaSe) cohort
UK model development cohort Sweden PCBase cohort
Total subjects 7063 69,206
Time at risk (years) 58,138 589,733
Range Range
Median follow-up (years) 9.8 0–16 13.9 0–17
Age (mean, SD) 69.9 8.34 68.8 8.83
PSA (mean, SD) 18.5 17.5 15.7 17.0
Grade groups % %
1 2317 32.8 36,992 53.5
2 2125 30.1 14,015 20.3
3 1057 15.0 7774 11.2
4 710 10.1 6345 9.2
5 854 12.1 4080 5.9
T stage
1 3761 53.2 35,700 51.6
2 2270 32.1 22,478 32.5
3 977 13.8 10,295 14.9
4 55 0.8 733 1.1
Primary treatment
Radical prostatectomy 995 14.1 20,936 30.3
Radical radiotherapy 2457 34.8 11,906 17.2
Androgen deprivation monotherapy 2226 31.5 15,980 23.1
Conservative management 1385 19.6 20,384 29.5
Comorbidity
No recorded comorbidity 6363 90.1 62,173 89.8
Comorbidity (Charlson Score ≥ 1) 700 9.9 7033 10.2
10-year outcomes
PCa death 712 6993
Non-PCa death 1555 15,122
Any-cause death 2267 22,115
Overall outcomes
PCa death 846 8151
Non-PCa death 1829 18,003
Any-cause death 2675 26,154
Crude PCS mortality rate (per patient year) 1.46 1.38
Annual overall mortality rate (per patient year) 4.60 4.43
PCa prostate cancer, SD standard deviation
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combination with the model’s baseline hazard functions
and time at risk to create individual estimates of un-
adjusted PCSM and NPCM over 15 years. These esti-
mates were adjusted for the competing risks between the
two causes of death to generate ACM estimates. To as-
sess discrimination, 15-year estimates were generated.
Harrell’s concordance index (c-index) was then applied
using the ‘Hmisc’ package in R [14]. Discrimination
using PREDICT Prostate was compared to the EAU and
NCCN stratification systems and the UCSF CAPRA
score [15–17]. Sub-classification of stage T2 was not
available; therefore, T2 was assumed to be T2a for the
sake of these classifications. When PPC was unknown, it
was assumed to be < 34% in the CAPRA model. Ad-
justed predictions of cumulative PCSM, NPCM and
ACM were generated using the available follow-up for
the assessment of model calibration. Calibration was
assessed using a chi-square goodness of fit (GOF) across
quintiles of risk using the method of May and Hosmer
[18]. Calibration was also assessed within treatment sub-
groups. All data analyses were performed in Stata™ 14,
unless otherwise stated above.
Results
Participants
Sixty-nine thousand two hundred six men were in-
cluded with 13.9 years of median follow-up. The
Swedish population attributes at baseline are com-
pared to the UK model development cohort in
Table 1. Patient characteristics were similar in both
cohorts, with a larger proportion of grade group 1
disease in the Swedish cohort. A larger proportion of
men underwent surgery as opposed to radiotherapy in
the Swedish cohort, and smaller proportion were
treated with primary androgen deprivation therapy in
this time period. Breakdown of the patients by risk
groups is reported in Additional file 1: Table S1.
Model performance
Overall discrimination of PREDICT Prostate was very
good with c-indices 0.85 (95% CI 0.85–0.86) for PCSM
and 0.79 (95% CI 0.79–0.79) for ACM (Table 2). Overall
calibration of the model was excellent with 25,925
deaths predicted and 25,849 deaths observed in PCBaSe.
This equates to an overall observed to expected (O:E) ra-
tio of 1:1.003. Calibration across quintiles of risk is
shown in Fig. 1 and Additional file 1: Table S2. Although
the O:E ratio for any-cause death was very close to 1, ex-
pected numbers of PCa deaths were slightly higher than
observed (O:E 0.897) and expected numbers of non-PCa
deaths were lower than observed (O:E 1.060), particu-
larly in the highest risk quintiles.
Treatment sub-groups
Overall, 20,384 men underwent conservative manage-
ment and 32,842 received radical treatment. Within
these groups, c-indices remained good, with c-index for
15-year PCSM 0.81 (95% CI 0.80–0.82) for conservative
management and 0.78 (95% CI 0.77–0.80) for radical
treatment (Table 2).
Among men on well-defined active surveillance, c-
indices were further improved at 0.88 for PCSM and
0.75 for ACM (Additional file 1: Table S3). Calibration
also remained good within treatment groups with differ-
ences between observed and predicted numbers of over-
all deaths 1.4%, 2.2% and 3.1% among men who received
active surveillance, radiotherapy and prostatectomy, re-
spectively (Table 3). The model overestimated PCSM
and underestimated NPCM within the sub-group which
received androgen deprivation monotherapy by as much
as 8%—but remained within 2% for overall death
(Table 3).
Comparison to existing models
PREDICT Prostate significantly outperformed the com-
parator models when predicting ACM, both overall and
Table 2 Discrimination of PREDICT Prostate (PREDICT) within treatment sub-groups and comparison to other existing tools
PCSM Overall
N Tool c-index SD p c-index SD p
Conservative management 20,384 PREDICT 0.810 0.010 0.740 0.0057
20,384 EAU 0.746 0.0115 < 0.001 0.636 0.0061 < 0.001
20,384 NCCN 0.760 0.0118 < 0.001 0.643 0.0063 < 0.001
20,384 CAPRA 0.765 0.0125 < 0.001 0.643 0.0064 < 0.001
Radical treatment 32,842 PREDICT 0.784 0.0122 0.670 0.0077
32,842 EAU 0.742 0.0113 < 0.001 0.606 0.0077 < 0.001
32,842 NCCN 0.769 0.0106 0.063 0.617 0.0081 < 0.001
32,842 CAPRA 0.780 0.0116 0.475 0.625 0.0082 < 0.001
Overall 69,206 PREDICT 0.852 0.0038 0.792 0.0028
EAU European Association of Urology criteria, NCCN National Cancer Care Network criteria, CAPRA UCSF Cancer of the prostate risk assessment criteria, SD
standard deviation
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within every major treatment sub-group (Table 2 and
Additional file 1: Table S3). Discriminatory performance
was significantly better for PCSM overall (Additional file
1: Table S4). Across all treatment sub-groups, the model
outperformed the 3-stratum EAU risk categories. Im-
provements in discrimination failed to reach significance
for PCSM in some comparisons with the NCCN and
CAPRA scores, but in only one incidence was the c-
index better for one of these comparator models
(CAPRA score for PCSM among RP patients, Additional
file 1: Table S3).
Biopsy parameter sub-analysis
Biopsy parameterisation using percentage of positive
cores (PPC) was re-explored within a group of 44,163
men who had this information registered (Additional file
1). Inclusion of biopsy characteristics did not signifi-
cantly alter the discriminatory performance of the model
(Additional file 1: Tables S4 & Table S5): either using a
dichotomous 50% percentage of cores cut-off or PPC as
a continuous variable. Inclusion of biopsy information
did improve calibration across lower-risk quintiles of
risk for PCSM. Calibration for any-cause death however
was unchanged regardless of inclusion of biopsy infor-
mation (Additional file 1: Table S6 & Figure S1).
Discussion
In this large external validation cohort, we demonstrated
that PREDICT Prostate is a robust and generalisable
long-term prognostic model. In the analysis of an inde-
pendent cohort, ten times larger than the original co-
hort, discriminatory accuracy and calibration was good.
This also remained true within treatment groups, par-
ticularly in men managed conservatively or by radical
therapy.
Conveying information to an individual about their
disease prognosis within their own context of competing
mortality has historically been an imprecise exercise with
little objective data available. The most current prognos-
tication is based on stratification groups of the cancer it-
self and discussions with clinicians who may be
conflicted towards a particular treatment [19–21]. PRE-
DICT Prostate was conceived to address this gap in clin-
ical need and standardise the decision-making process
[3] and has shown promise to positively influence clin-
ical decision-making [22]. It is built around long-term
actual survival data and has been designed to address all
AJCC criteria [6].
In the model development study, c-indices were 0.84
for PCSM and 0.77 for ACM within the UK validation
cohort [3]. In the original study, external validity was
Fig. 1 Calibration curves demonstrating observed and expected 15-year probability of death across quintiles or risk for prostate cancer (PCa)
death (left), non-PCa death (centre) and any-cause death (right)
Table 3 Calibration of PREDICT Prostate mortality estimates with observed numbers of deaths within treatment groups
PCa death Non-PCa death Any-cause death
n Obs Pred % Diff Obs Pred % Diff Obs Pred % Diff
‘Active surveillance’ 6224 195 191 0.06 850 940 1.44 1045 1131 1.38
‘Watchful waiting’ 2745 239 198 1.49 942 915 0.98 1181 1112 2.51
‘Other conservative’ 11,415 1358 1373 0.13 4906 4535 3.25 6264 5908 3.12
Radical prostatectomy 20,936 550 703 0.73 1919 2403 2.31 2469 3107 3.05
Radiotherapy 8953 737 560 1.94 1591 1594 0.03 2318 2155 2.18
ADT 15,980 4809 5798 6.19 7215 5993 7.65 12,024 11,792 1.45
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also assessed within a Singaporean cohort. However, this
cohort was small (n = 2546) and follow-up was quite
short (5.1 years). Here we show in a cohort of > 69,000
men with longer median follow-up that our c-indices
were actually improved to 0.85 for PCSM and 0.79 for
ACM with excellent calibration. We did note a marginal
overestimation of PCSM, which was contrary to the
slight underestimation we had observed in the Singapore
external validation in the original paper [3]. Given that
the model is very well calibrated for ACM, this apparent
overestimation of PCSM (and corresponding underesti-
mation of NPCM) is likely to be a result of differences in
cause of death classification, reporting or recording
practices. ACM is the key outcome of interest, and a
more unequivocal endpoint, against which this model
performs very well.
When compared to existing models, PREDICT Pros-
tate consistently outperformed the three-stratum risk
classification system used in the EAU, D’Amico and
NICE stratification criteria [16, 20, 23]. We recognise
that comparisons against these risk stratification criteria
are limited and that they are not designed to be prog-
nostic nomograms; however, they are widely used in
clinical practice to inform treatment decisions. Benefits
of PREDICT were also seen against the NCCN and
CAPRA scores, which add more granularity but ultim-
ately retain a grouping system rather than individual es-
timates [16, 17]. For the outcome of PCSM, the CAPRA
score did perform similarly well for some treatment
groups, particularly in men treated with prostatectomy.
This is unsurprising, as the model was originally built
around prostatectomy patients [24]. It should be noted
that PREDICT Prostate is not a treatment-specific tool;
therefore, by assessing discrimination within treatment
sub-groups, its discriminatory performance will inevit-
ably be reduced. Nonetheless, PREDICT Prostate per-
formed significantly better in predicting ACM and
PCSM in most treatment groups. We also confirmed
that adding in biopsy data to the model improved the
performance though this effect was marginal in addition
to the other variables already included. Using PPC as a
continuous variable maximises the use of prognostic in-
formation, and this parameterisation did lead to margin-
ally superior discrimination for ACM.
The primary utility of PREDICT Prostate will be in
men for whom conservative management and radical
treatment might both be appropriate options, for whom
the decision is most difficult. Abundant literature dem-
onstrates that decision aids contribute to more
knowledgeable and informed patients and that they can
improve clinician-patient communication [25, 26].
Therefore, the model may have wide potential applica-
tions in informing patient, clinician and multi-
disciplinary team decision-making to reduce both over-
and under-treatment. Formal clinical impact assessments
are also crucial to show face and functional validity, and
these are underway with PREDICT Prostate [27]. Future
research endeavours could assess what impact the use of
the model might have on actual treatment practices and
compare this model with prognostic biomarkers, or
radiological prognosticators. Over time, additional pa-
rameters can be incorporated into this base model, or
the model itself be updated, should new variables be
shown to have independent prognostic effects [28].
More recent efforts in prognostic tools have sought to
utilise novel genomic or biological markers to generate
prognostic estimates. However, most established gen-
omic tools such as Prolaris CCP and Oncotype DX GPS
have predominantly been tested against shorter-term
outcomes or in treatment-specific cohorts [29, 30].
Where they have been assessed against PCSM, concord-
ance has been very similar to our model—for example,
the Decipher genomic classifier alongside CAPRA
showed an AUC of 0.78 (95% CI 0.68–0.87) for 10-year
PCSM following prostatectomy [31]. Direct comparison
with PREDICT Prostate is not possible without a head-
to-head or combined study, but the value of such expen-
sive tests do need to be re-assessed in the context of
optimised clinical multivariable models [32]. In this con-
text, we would welcome collaborations or independent
studies on the value of adding genomic classifiers to fu-
ture iterations of PREDICT Prostate.
This study has numerous strengths, given the large
sample size, long follow-up and high completeness of
data in PCBaSe [33]. However, we recognise limitations
inherent to using registry data. Seventeen per cent of
men were excluded due to missing data, and we cannot
exclude this, introducing some bias. A large proportion
of men within this validation dataset had low-grade dis-
ease, such that PCa mortality rates were relatively low
which may affect discriminatory performance. Men diag-
nosed within the inclusion period may also not be repre-
sentative of contemporary practice with changes in PCa
diagnosis and treatment. For instance, we recognise that
primary hormone therapy is now rarely used in the con-
text of non-metastatic PCa; hence, we included sub-
group analyses within other treatment groups. We also
appreciate that multi-modal therapies are increasingly
used in higher risk cases, which we were not able to as-
sess in this study due to the inclusion dates and data
availability limitations of our datasets. Another particular
concern is the lack of information from magnetic reson-
ance imaging (MRI). However, the current focus for
MRI is on tumour detection rather than prognostication
and it is unknown if MRI lesion characteristics (Likert
or PIRAD scoring) have any bearing on survival. Our
model also cannot account for subsequent transitions to
different treatments. However, in our UK dataset,
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conversions to active treatment were less than 6% across
total follow-up [3]. We also recognise the lack of T-stage
sub-classification, which is a key parameter in 2 of the
existing models we made comparisons to. However, it is
accepted that T stage is often inaccurately assigned in
localised disease [34]. We also recognise that other end-
points of interest exist, particularly the development of
metastases and commencement of hormone therapy.
The model is untested against these endpoints, but cali-
brated against the more robust endpoint of death.
A key issue going forward is the validation of this
model in non-Caucasian and screened populations. Al-
though the original paper re-tested the model in Singa-
porean men, PREDICT Prostate remains untested in
men of African descent or other ethnicities. Independent
validations within screened populations, and within
other prospectively collected or randomised datasets,
would also be helpful and should be encouraged. Finally,
we recognise that other nomograms are available, against
which direct comparisons would be very insightful.
These were not possible within the design of this study,
or the limitations of this data, particularly with regard to
comorbidity.
Conclusions
This large external validation demonstrates the robust-
ness of PREDICT Prostate. PREDICT Prostate, available
as a free-to-use web tool [4], has the potential to signifi-
cantly improve shared decision-making for PCa manage-
ment, particularly the choice between conservative
management and radical treatment. Further, independ-
ent external validations are encouraged, especially in
populations of different ethnicities.
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